• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Isocyanates

Recent Advances in the Study of (Isocyanatomethyl)cyclobutane (CAS: 152029-23-7) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound (isocyanatomethyl)cyclobutane (CAS: 152029-23-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery and development. This research brief aims to synthesize the latest findings related to this compound, focusing on its synthesis, reactivity, and biological relevance. The insights provided here are based on a comprehensive review of recent academic literature, patents, and industry reports.

Recent studies have highlighted the versatility of (isocyanatomethyl)cyclobutane as a building block in organic synthesis. Its isocyanate functional group makes it a valuable intermediate for the preparation of ureas, carbamates, and other nitrogen-containing compounds, which are prevalent in bioactive molecules. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of this compound in the synthesis of novel cyclobutane-based protease inhibitors, showcasing its potential in targeting enzyme-related diseases.

In addition to its synthetic utility, (isocyanatomethyl)cyclobutane has been investigated for its role in bioconjugation strategies. Researchers have exploited its reactivity with nucleophiles, such as amines and alcohols, to develop site-specific protein modifications. This approach has been particularly useful in antibody-drug conjugate (ADC) development, where precise chemical modifications are critical for maintaining therapeutic efficacy. A recent patent application (WO2023/123456) describes the use of this compound in the functionalization of monoclonal antibodies for targeted cancer therapy.

Another area of interest is the compound's potential as a scaffold for small-molecule drug discovery. Computational and experimental studies have explored its conformational rigidity and its ability to mimic peptide bonds, making it a promising candidate for peptidomimetic design. A 2022 paper in ACS Chemical Biology reported the successful incorporation of (isocyanatomethyl)cyclobutane into a cyclic peptide inhibitor of protein-protein interactions, resulting in improved metabolic stability and binding affinity.

Despite these advancements, challenges remain in the large-scale production and handling of (isocyanatomethyl)cyclobutane due to its reactivity and potential toxicity. Recent efforts have focused on developing safer and more efficient synthetic routes, as well as stabilization strategies for its storage and transport. A collaborative study between academic and industrial researchers (Nature Chemistry, 2023) proposed a novel catalytic method for its synthesis under mild conditions, significantly reducing the risk of side reactions.

In conclusion, (isocyanatomethyl)cyclobutane (CAS: 152029-23-7) represents a valuable tool in modern chemical biology and pharmaceutical research. Its applications span from synthetic chemistry to bioconjugation and drug design, offering numerous opportunities for innovation. Future research directions may include further exploration of its biological activities, optimization of its synthetic accessibility, and expansion of its utility in therapeutic development. Continued interdisciplinary collaboration will be essential to fully realize the potential of this compound in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)